Date | Title | Description | |
---|---|---|---|
15 Mar 2022 | On significant placements in financial instruments | Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. | Download |
14 Mar 2022 | On significant placements in financial instruments | Bestinver announces the beginning of an accelerated book building process approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. | Download |
23 Feb 2022 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
23 Feb 2022 | On business and financial situation | The Company releases the press release related to the full year 2021 financial results | Download |
23 Feb 2022 | On business and financial situation | The Company releases the full year 2021 financial results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
16 Jun 2022 | Other relevant information | The Company has agreed to execute the capital reduction approved by the 2022 Ordinary General Meeting to amortize the shares acquired in the framework of the own shares repurchase programs | Download |
14 Jun 2022 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
11 May 2022 | On business and financial situation | The Company releases the press release related to the first quarter 2022 financial result | Download |
11 May 2022 | On business and financial situation | The Company releases the first quarter 2022 financial results presentation | Download |
11 May 2022 | Announcement of general shareholders’ meeting | Rovi releases the information related to its 2022 General Shareholders Meeting | Download |
Pages
Date | Title | Description | |
---|---|---|---|
26 Feb 2019 | Información sobre resultados | ROVI releases the presentation related to the full year 2018 results | Download |
26 Feb 2019 | Información sobre resultados | ROVI releases the press release related to the full year 2018 results | Download |
15 Feb 2019 | Others on business performance and financial information | ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets | Download |
09 Jan 2019 | Others on business performance and financial information | ROVI informs about the adquisition of Falithrom® for the German market | Download |
08 Jan 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2018 | Download |